|
| | Publication Year | Title | Author(s) |
| 1 | 31-Oct-2020 | BCL-XL is an actionable target for treatment of malignant pleural mesothelioma. | Arulananda, Surein; O'Brien, Megan; Evangelista, Marco; Harris, Tiffany J ; Steinohrt, Nikita S; Jenkins, Laura J; Walkiewicz, Marzena; O'Donoghue, Robert J J; Poh, Ashleigh R; Thapa, Bibhusal ; Williams, David S ; Leong, Trishe; Mariadason, John M; Li, Xia; Cebon, Jonathan S ; Lee, Erinna F; John, Thomas ; Fairlie, Walter Douglas |
| 2 | 16-Sep-2020 | Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma. | Faridi, Pouya; Woods, Katherine; Ostrouska, Simone; Deceneux, Cyril; Aranha, Ritchlynn; Duscharla, Divya; Wong, Stephen Q; Chen, Weisan; Ramarathinam, Sri H; Lim Kam Sian, Terry C C; Croft, Nathan P; Li, Chen; Ayala, Rochelle; Cebon, Jonathan S ; Purcell, Anthony W; Schittenhelm, Ralf B; Behren, Andreas |
| 3 | 7-Sep-2020 | Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report. | Hultin, Sebastian; Nahar, Kazi; Menzies, Alexander M; Long, Georgina V; Fernando, Suran L; Atkinson, Victoria; Cebon, Jonathan S ; Wong, Muh Geot |
| 4 | 1-Sep-2020 | Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial. | Klein, Oliver ; Kee, Damien ; Nagrial, Adnan; Markman, Ben; Underhill, Craig; Michael, Michael; Jackett, Louise A ; Lum, Caroline; Behren, Andreas; Palmer, Jodie; Tebbutt, Niall C ; Carlino, Matteo S; Cebon, Jonathan S |
| 5 | Jul-2020 | Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141+ dendritic cells to activate naïve and memory NY-ESO-1-specific CD8+ T cells. | Masterman, Kelly-Anne; Haigh, Oscar L; Tullett, Kirsteen M; Leal-Rojas, Ingrid M; Walpole, Carina; Pearson, Frances E; Cebon, Jonathan S ; Schmidt, Christopher; O'Brien, Liam; Rosendahl, Nikita; Daraj, Ghazal; Caminschi, Irina; Gschweng, Eric H; Hollis, Roger P; Kohn, Donald B; Lahoud, Mireille H; Radford, Kristen J |
| 6 | 30-Jun-2020 | Long-Term Follow-Up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients With Advanced Melanoma: KEYNOTE-029 Part 1B. | Carlino, Matteo S; Menzies, Alexander M; Atkinson, Victoria G; Cebon, Jonathan S ; Jameson, Michael B; Fitzharris, Bernard M; McNeil, Catriona M; Hill, Andrew Graham; Ribas, Antoni; Atkins, Michael B; Thompson, John A; Hwu, Wen-Jen; Hodi, F Stephen; Guminski, Alexander; Kefford, Richard F; Wu, Haiyan; Ibrahim, Nageatte; Homet Moreno, Blanca; Long, Georgina V |
| 7 | 24-Jun-2020 | Distinctive subpopulations of stromal cells are present in human lymph nodes infiltrated with melanoma. | Eom, Jennifer; Park, Saem Mul; Feisst, Vaughan; Chen, Chun-Jen J; Mathy, Joanna E; McIntosh, Julie D; Angel, Catherine E; Bartlett, Adam; Martin, Richard; Mathy, Jon A; Cebon, Jonathan S ; Black, Michael A; Brooks, Anna E S; Dunbar, P Rod |
| 8 | 12-Jun-2020 | Immunotherapy of Ipilimumab and Nivolumab in patients with advanced neuroendocrine tumours: a subgroup analysis of the CA209-538 clinical trial for rare cancers. | Klein, Oliver ; Kee, Damien ; Markman, Ben; Michael, Michael; Underhill, Craig R; Carlino, Matteo S; Jackett, Louise A ; Lum, Caroline; Scott, Clare L; Nagrial, Adnan; Behren, Andreas; So, Jane Yeojeong; Palmer, Jodie; Cebon, Jonathan S |
| 9 | Apr-2020 | A distinct pre-treatment immune gene signature in lentigo maligna is associated with imiquimod response. | Halse, Heloise; Caramia, Franco; McLean, Catriona A; Wang, Minyu; Aw Yeang, Han Xian; Keam, Simon P; Behren, Andreas; Ly, Lena; Haskett, Martin; Cebon, Jonathan S ; McArthur, Grant A; Neeson, Paul J; Mar, Victoria J |
| 10 | Apr-2020 | Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma. | Cebon, Jonathan S ; Gore, Martin; Thompson, John F; Davis, Ian D; McArthur, Grant A; Walpole, Euan; Smithers, Mark; Cerundolo, Vincenzo; Dunbar, P Rod; MacGregor, Duncan; Fisher, Cyril; Millward, Michael; Nathan, Paul; Findlay, Michael P N; Hersey, Peter; Evans, T R Jeffry; Ottensmeier, Christian Hermann; Marsden, Jeremy; Dalgleish, Angus G; Corrie, Pippa G; Maria, Marples; Brimble, Margaret; Williams, Geoff; Winkler, Sintia; Jackson, Heather M; Endo-Munoz, Liliana; Tutuka, Candani S A; Venhaus, Ralph; Old, Lloyd J; Haack, Dennis; Maraskovsky, Eugene; Behren, Andreas; Chen, Weisan |
| 11 | 7-Feb-2020 | Butyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cells. | Rigau, Marc; Ostrouska, Simone; Fulford, Thomas S; Johnson, Darryl N; Woods, Katherine; Ruan, Zheng; McWilliam, Hamish E G; Hudson, Christopher; Tutuka, Candani; Wheatley, Adam K; Kent, Stephen J; Villadangos, Jose A; Pal, Bhupinder; Kurts, Christian; Simmonds, Jason; Pelzing, Matthias; Nash, Andrew D; Hammet, Andrew; Verhagen, Anne M; Vairo, Gino; Maraskovsky, Eugene; Panousis, Con; Gherardin, Nicholas A; Cebon, Jonathan S ; Godfrey, Dale I; Behren, Andreas; Uldrich, Adam P |
| 12 | Feb-2020 | Tracking extracellular vesicle phenotypic changes enables treatment monitoring in melanoma. | Wang, Jing; Wuethrich, Alain; Sina, Abu Ali Ibn; Lane, Rebecca E; Lin, Lynlee L; Wang, Yuling; Cebon, Jonathan S ; Behren, Andreas; Trau, Matt |
| 13 | Oct-2019 | Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program. | Martin-Algarra, Salvador; Hinshelwood, Rebecca; Mesnage, Soizick; Cebon, Jonathan S ; Ferrucci, Pier Francesco; Aglietta, Massimo; Neyns, Bart; Chiarion-Sileni, Vanna; Lindsay, Colin R; Del Vecchio, Michele; Linardou, Helen; Merelli, Barbara; Tonini, Giuseppe; Atkinson, Victoria; Freivogel, Klaus; Stein, Dara; Dalland, Lindi; Lau, Mike; Legenne, Philippe; Queirolo, Paola; Millward, Michael |
| 14 | 5-Sep-2019 | Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature. | Gunjur, Ashray ; Klein, Oliver ; Kee, Damien ; Cebon, Jonathan S |
| 15 | Aug-2019 | A pilot study of intrahepatic yttrium-90 microsphere radioembolization in combination with intravenous cisplatin for uveal melanoma liver-only metastases. | Arulananda, Surein; Parakh, Sagun ; Palmer, Jodie; Goodwin, Mark D ; Andrews, Miles C; Cebon, Jonathan S |
| 16 | May-2019 | Genomic Analysis of Circulating Tumor DNA Using a Melanoma-Specific UltraSEEK Oncogene Panel. | Gray, Elin S; Witkowski, Tom ; Pereira, Michelle; Calapre, Leslie; Herron, Karl; Irwin, Darryl; Chapman, Brett; Khattak, Muhammad A; Raleigh, Jeanette; Hatzimihalis, Athena; Cebon, Jonathan S ; Sandhu, Shahneen; McArthur, Grant A; Millward, Michael; Ziman, Melanie; Dobrovic, Alexander ; Wong, Stephen Q |
| 17 | 24-Apr-2019 | BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival. | Lee, Erinna F; Harris, Tiffany J ; Tran, Sharon; Evangelista, Marco; Arulananda, Surein; John, Thomas ; Ramnac, Celeste; Hobbs, Chloe; Zhu, Haoran; Gunasingh, Gency; Segal, David; Behren, Andreas; Cebon, Jonathan S ; Dobrovic, Alexander ; Mariadason, John M; Strasser, Andreas; Rohrbeck, Leona; Haass, Nikolas K; Herold, Marco J; Fairlie, W Douglas |
| 18 | Feb-2019 | Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma. | Parakh, Sagun ; Randhawa, Manreet; Nguyen, Bella; Warburton, Lydia; Hussain, Mohammad Akhtar; Cebon, Jonathan S ; Millward, Michael; Yip, Desmond; Ali, Sayed |
| 19 | Dec-2018 | Perspective: cancer vaccines in the era of immune checkpoint blockade. | Cebon, Jonathan S |
| 20 | 22-Nov-2018 | Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy. | Liew, David F L ; Leung, Jessica L Y ; Liu, Bonnia ; Cebon, Jonathan S ; Frauman, Albert G ; Buchanan, Russell R C |
Loading...
2
0
5
0
false
0000-0002-3898-950x